Login to Your Account



Endo Licenses Cancer Pain Product Rapinyl From Orexo

By Karen Pihl-Carey


Thursday, August 19, 2004
Upon disclosing the completion of one licensing deal for a migraine drug, Endo Pharmaceuticals Inc. said it has entered another - the second, an agreement for development and marketing rights to a breakthrough cancer pain product. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription